Iron-overload injury and cardiomyopathy in acquired and genetic models is attenuated by resveratrol therapy

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Das, Subhash K ^a,b   Wang, Wang ^b,c   Zhabyeyev, Pavel ^a,b   Basu, Ratnadeep ^a,b   Mclean, Brent ^b,c   Fan, Dong ^b,c   Parajuli, Nirmal ^a,b   Desaulniers, Jessica ^a,b   Patel, Vaibhav B ^a,b   Hajjar, Roger J ^d   Dyck, Jason R B ^c   Kassiri, Zamaneh ^b,c   Oudit, Gavin Y ^a,b  

^a Division of Cardiology   (United States)

^b MAZANKOWSKI ALBERTA HEART INSTITUTE   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FORKHEAD TRANSCRIPTION FACTOR; FOXO1 PROTEIN, MOUSE; HFE2 PROTEIN, MOUSE; MEMBRANE PROTEIN; OXIDIZING AGENT; RESVERATROL; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SIRTUIN 1; STILBENE DERIVATIVE; TRANSCRIPTION FACTOR FKHR;

ANIMAL; BIOLOGICAL MODEL; C57BL MOUSE; CARDIAC MUSCLE; CARDIAC MUSCLE CELL; CARDIOMYOPATHIES; COMPLICATION; DEFICIENCY; DISEASE MODEL; DOWN REGULATION; DRUG EFFECTS; FIBROBLAST; FIBROSIS; GENE THERAPY; HUMAN; IRON OVERLOAD; KNOCKOUT MOUSE; MALE; METABOLISM; OXIDATIVE STRESS; PATHOLOGY; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CARDIOMYOPATHIES; DISEASE MODELS, ANIMAL; DOWN-REGULATION; FIBROBLASTS; FIBROSIS; FORKHEAD BOX PROTEIN O1; FORKHEAD TRANSCRIPTION FACTORS; GENETIC THERAPY; HUMANS; IRON OVERLOAD; MALE; MEMBRANE PROTEINS; MICE, INBRED C57BL; MICE, KNOCKOUT; MODELS, GENETIC; MYOCARDIUM; MYOCYTES, CARDIAC; OXIDANTS; OXIDATIVE STRESS; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; SIGNAL TRANSDUCTION; SIRTUIN 1; STILBENES;

EID: 84949502640     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep18132     Document Type: Article

References (56)

1. Barton J. C., & Bertoli L. F. Hemochromatosis: the genetic disorder of the twenty-first century. Nat. Med. 2, 394-395 (1996).
2. Andrews N. C. Disorders of iron metabolism. N. Engl. J. Med. 341, 1986-1995 (1999).
3. Pietrangelo A. Hereditary hemochromatosis-A new look at an old disease. N. Engl. J. Med. 350, 2383-2397 (2004).
4. Fleming R. E., & Ponka P. Iron overload in human disease. N. Engl. J. Med. 366, 348-359 (2012).
5. Murphy C. J., & Oudit G. Y. Iron-overload cardiomyopathy: pathophysiology, diagnosis, and treatment. J. Card. Fail. 16, 888-900 (2010).
6. Pennell D. J., et al. Cardiovascular function and treatment in beta-Thalassemia major: a consensus statement from the American Heart Association. Circulation. 128, 281-308 (2013).
7. Weatherall D. J., & Clegg J. B. Thalassemia-A global public health problem. Nat. Med. 2, 847-849 (1996).
8. Felker G. M., et al. Underlying causes and long-Term survival in patients with initially unexplained cardiomyopathy. N. Engl. J. Med. 342, 1077-1084 (2000).
9. Olivieri N. F., et al. Survival in medically treated patients with homozygous beta-Thalassemia. N. Engl. J. Med. 331, 574-578 (1994).
10. Allen K. J., et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N. Engl. J. Med. 358, 221-230 (2008).
11. Olynyk J. K., et al A population-based study of the clinical expression of the hemochromatosis gene. N. Engl. J. Med. 341, 718-724 (1999).
12. Brittenham G. M., et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N. Engl. J. Med. 331, 567-573 (1994).
13. Hannuksela J., et al. Hereditary hemochromatosis gene (HFE) mutations C282Y, H63D and S65C in patients with idiopathic dilated cardiomyopathy. Eur. J. Heart Fail. 7, 103-108 (2005).
14. Buja L. M., & Roberts W. C. Iron in the heart. Etiology and clinical significance. Am. J. Med. 51, 209-221 (1971).
15. Hentze M. W., Muckenthaler M. U., & Andrews N. C. Balancing acts: molecular control of mammalian iron metabolism. Cell. 117, 285-297 (2004).
16. Oudit G. Y., et al. L-Type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat. Med. 9, 1187-1194 (2003).
17. Tsushima R. G., et al. Modulation of iron uptake in heart by L-Type Ca2+ channel modifiers: possible implications in iron overload. Circ. Res. 84, 1302-1309 (1999).
18. Oudit G. Y., et al. Taurine supplementation reduces oxidative stress and improves cardiovascular function in an iron-overload murine model. Circulation. 109, 1877-1885 (2004).
19. Perdomini M., et al. Prevention and reversal of severe mitochondrial cardiomyopathy by gene therapy in a mouse model of Friedreich?s ataxia. Nat. Med. 20, 542-547 (2014).
20. Goldhaber J. I., & Qayyum M. S. Oxygen free radicals and excitation-contraction coupling. Antioxid. Redox Signal. 2, 55-64 (2000).
21. Livrea M. A., et al. Oxidative stress and antioxidant status in beta-Thalassemia major: iron overload and depletion of lipid-soluble antioxidants. Blood. 88, 3608-3614 (1996).
22. Eaton J. W., & Qian M. Molecular bases of cellular iron toxicity. Free Radic. Biol. Med. 32, 833-840 (2002).
23. Becker L. B. New concepts in reactive oxygen species and cardiovascular reperfusion physiology. Cardiovasc. Res. 61, 461-470 (2004).
24. Huang F. W., Pinkus J. L., Pinkus G. S., Fleming M. D., & Andrews N. C A mouse model of juvenile hemochromatosis. J. Clin. Invest. 115, 2187-2191 (2005).
25. Wood J. C., et al. Cardiac iron determines cardiac T2, T2, and T1 in the gerbil model of iron cardiomyopathy. Circulation. 112, 535-543 (2005).
26. Lagouge M., et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell. 127, 1109-1122 (2006).
27. Milne J. C., et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. 450, 712-716 (2007).
28. Lavu S., Boss O., Elliott P. J., & Lambert P. D. Sirtuins-novel therapeutic targets to treat age-Associated diseases. Nat. Rev. Drug Discov. 7, 841-853 (2008).
29. Baur J. A., et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 444, 337-342 (2006).
30. Baur J. A., & Sinclair D. A. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov. 5, 493-506 (2006).
31. Brunet A., et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science. 303, 2011-2015 (2004).
32. Price N. L., et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab. 15, 675-690 (2012).
33. Um, J. H., et al. AMP-Activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes. 59, 554-563 (2010).
34. Mitchell S. J., et al. The SIRT1 activator SRT1720 extends lifespan and improves health of mice fed a standard diet. Cell Rep. 6, 836-843 (2014).
35. Niederkofler V., Salie R., & Arber S. Hemojuvelin is essential for dietary iron sensing, and its mutation leads to severe iron overload. J. Clin. Invest. 115, 2180-2186 (2005).
36. Borra M. T., Smith B. C., & Denu J. M. Mechanism of human SIRT1 activation by resveratrol. J. Biol. Chem. 280, 17187-17195 (2005).
37. Crowell J. A., Korytko P. J., Morrissey R. L., Booth T. D., & Levine B. S. Resveratrol-Associated renal toxicity. Toxicol. Sci. 82, 614-619 (2004).
38. Sung M. M., et al. Resveratrol treatment of mice with pressure-overload-induced heart failure improves diastolic function and cardiac energy metabolism. Circ. Heart Fail. 8, 128-137 (2015).
39. Hajjar R. J. Potential of gene therapy as a treatment for heart failure. J. Clin. Invest. 123, 53-61 (2013).
40. Cutler M. J., et al. Targeted sarcoplasmic reticulum Ca2+ ATPase 2a gene delivery to restore electrical stability in the failing heart. Circulation. 126, 2095-2104 (2012).
41. Balderas-Villalobos J., et al. Oxidative stress in cardiomyocytes contributes to decreased SERCA2a activity in rats with metabolic syndrome. Am. J. Physiol. Heart Circ. Physiol. 305, H1344-1353 (2013).
42. Kho C., et al. SUMO1-dependent modulation of SERCA2a in heart failure. Nature. 477, 601-605 (2011).
43. Lee A., et al. The role of SUMO-1 in cardiac oxidative stress and hypertrophy. Antioxid. Redox Signal. 21, 1986-2001 (2014).
44. Zhong J., et al. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation. 122, 717-728 (2010).
45. Patel V. B., et al. Loss of angiotensin-converting enzyme-2 exacerbates diabetic cardiovascular complications and leads to systolic and vascular dysfunction: a critical role of the angiotensin II/AT1 receptor axis. Circ. Res. 110, 1322-1335 (2012).
46. Wang W., et al. Loss of Apelin exacerbates myocardial infarction adverse remodeling and ischemia-reperfusion injury: therapeutic potential of synthetic Apelin analogues. J. Am. Heart Assoc. 2, e000249 (2013).
47. Mori J., et al. Angiotensin 1-7 ameliorates diabetic cardiomyopathy and diastolic dysfunction in db/db mice by reducing lipotoxicity and inflammation. Circ. Heart Fail. 7, 327-339 (2014).
48. Mori J., et al. Agonist-induced hypertrophy and diastolic dysfunction are associated with selective reduction in glucose oxidation: a metabolic contribution to heart failure with normal ejection fraction. Circ. Heart Fail. 5, 493-503 (2012).
49. Patel V. B., et al. Loss of p47phox subunit enhances susceptibility to biomechanical stress and heart failure because of dysregulation of cortactin and actin filaments. Circ. Res. 112, 1542-1556 (2013).
50. Erdelmeier I., Gerard-Monnier D., Yadan J. C., & Chaudiere J. Reactions of N-methyl-2-phenylindole with malondialdehyde and. 4-hydroxyalkenals. Mechanistic aspects of the colorimetric assay of lipid peroxidation. Chem. Res. Toxicol. 11, 1184-1194 (1998).
51. Rahman I., Kode A., & Biswas S. K. Assay for quantitative determination of glutathione and glutathione disulfide levels using enzymatic recycling method. Nat. Protoc. 1, 3159-3165 (2006).
52. O'Connell T. D., Rodrigo M. C., & Simpson P. C. Isolation and culture of adult mouse cardiac myocytes. Methods Mol. Biol. 357, 271-296 (2007).
53. Parkes J. G., Liu Y., Sirna J. B., & Templeton D. M. Changes in gene expression with iron loading and chelation in cardiac myocytes and non-myocytic fibroblasts. J. Mol. Cell. Cardiol. 32, 233-246 (2000).
54. del Monte F., et al. Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a. Circulation. 100, 2308-2311 (1999).
55. Bird S. D., et al. The human adult cardiomyocyte phenotype. Cardiovasc. Res. 58, 423-434 (2003).
56. Kawano H., et al. Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts. Circulation. 101, 1130-1137 (2000).